PRESS RELEASE

innate pharma

INNATE PHARMA ANNOUNCES DATA PRESENTATIONS ON MONALIZUMAB AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY ANNUAL MEETING 2018

- ***Management to host KOL call on updated data from the ongoing Phase II trial of monalizumab and cetuximab on Monday, October 22, 4pm CEST (10 am EDT)***

Marseille, France, October 16, 2018, 07:00 AM CEST

Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 – IPH) today announced that updated data from ongoing clinical trials evaluating lead asset, monalizumab, partnered with AstraZeneca/MedImmune, will be presented at the ESMO 2018 Congress in Munich, Germany, October 19-23, 2018. Eric Vivier, Chief Scientific Officer, is invited to the ESMO Congress as speaker in the Early detection of cancer using minimally invasive biomarkers Special Symposium.

A KOL call will be held Monday, October 22, at 4pm CEST (10 am EDT)

Dial in numbers:

France and International: +33 (0)1 72 72 74 03 US only: +1 646 722 4916

PIN code: 69616804#

The presentation will be made available on the Company's website 30 minutes before the conference begins.

A replay will be available on Innate Pharma's website after the conference call.

Posters and presentation details:

- Title: Results of a Phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
- Date and time: October 20, 2018, 15:00
- Presentation number: 1049PD
- Session: Poster Discussion session – Head and neck
- Presenter: Jérôme Fayette, Medical Oncologist at the Centre Léon Bérard Lyon, France
- Location: Hall B3 – Room 23, ICM München, Munich, Germany

- Title: Translational endpoints in patients with metastatic microsatellite-stable colorectal cancer (MSS-CRC) treated with durvalumab plus monalizumab (anti-NKG2A)

- Date & time: October 20, 2018, 12:30
- Presentation number: 1194P
- Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
- Presenter: Jennifer R. Diamond, Associate Professor, Division of Medical Oncology at the Colorado University, Denver, US
- Location: Hall A3, Poster Area Networking Hub, ICM München, Munich, Germany

- Title: Changes in the innate immune system as early events in cancer
- Date & time: October 22, 2018, 15:05 – 15:25
- Session: Special Symposium
- Session Name: Early detection of cancer using minimally invasive biomarkers
- Presenter: Eric Vivier, Chief Scientific Officer of Innate Pharma, Marseille, France
- Location: Hall A1 – Room 17, ICM München, Munich, Germany

The posters will be made available on the Company's website after the session.

About Innate Pharma:

Innate Pharma S.A. is a clinical-stage biotechnology company dedicated to improving cancer treatment and clinical outcomes for patients through first-in-class therapeutic antibodies that harness the body's own immune system.

Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells.

The company's broad pipeline includes several first-in-class clinical stage antibodies as well as preclinical candidates and technologies that have the potential to address a broad range of cancer indications with high unmet medical needs.

Innate Pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of Natural Killer cell biology. This innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi. Innate Pharma is building the foundations to become a fully-integrated biopharmaceutical company.

Based in Marseille, France, Innate Pharma has more than 190 employees and is listed on Euronext Paris.

Learn more about Innate Pharma at www.innate-pharma.com

PRESS RELEASE

innate pharma

Information about Innate Pharma shares:

ISIN code	FR0010331421
Ticker code	IPH
LEI	9695002Y8420ZB8HJE29

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the *Document de Reference* prospectus filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma’s website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Investors

Innate Pharma

Dr. Markus Metzger / Danielle Spangler / Jérôme Marino

Tel.: +33 (0)4 30 30 30 30

investors@innate-pharma.com

International Media

Consilium Strategic Communications

Mary-Jane Elliott / Jessica Hodgson

Tel.: +44 (0)20 3709 5700

InnatePharma@consilium-comms.com

French Media

ATCG Press

Marie Puvieux

Mob: +33 (0)6 10 54 36 72

presse@atcg-partners.com